[et_pb_section fb_built=”1″ specialty=”on” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.7″ _module_preset=”default” header_2_font=”Lato|700|||||||” header_2_text_color=”#83004A” header_2_font_size=”30px” hover_enabled=”0″ locked=”off” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”Lato||||||||” text_font_size=”15px” header_3_font=”Lato|600|||||||” header_3_text_color=”#951542″ header_3_font_size=”19px” locked=”off” global_colors_info=”{}”]<\/p>\n
Elisa Oricchio is the Director of the Swiss Institute for Experimental Cancer Research (ISREC) and a professor at EPFL in Lausanne (Switzerland).<\/span> Her work has been recognized with the Blavatnik Award for Young Scientist by the New York Academy of Science, the Lorini Award for Italian Scientist in Cancer Research, and in 2021 she received the Prix Leenaards for Translation Research.<\/span><\/p>\n Elisa Oricchio delivered the prestigious Pezcoller Foundation \u2013 EACR Translational Cancer Researcher Award Lecture at the EACR 2024 Congress, Rotterdam, June 10. She also held a lecture at the\u00a0<\/span>University of Trento, Italy<\/strong>, on\u00a0<\/span>November 26, 2024<\/strong>.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.pezcoller.it\/wp-content\/uploads\/2025\/01\/img_8224.jpg” title_text=”img_8224″ _builder_version=”4.27.4″ _module_preset=”default” border_radii=”off|36px|36px|36px|36px” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.27.7″ _module_preset=”default” text_font=”Lato||||||||” text_text_color=”#FFFFFF” text_font_size=”15px” background_color=”#83004A” custom_margin=”0px||||false|false” custom_padding=”20px|25px|20px|25px|true|true” hover_enabled=”0″ border_radii=”on|36px|36px|36px|36px” locked=”off” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
She received her Ph.D. in 2008 and did her post-doctoral training at Memorial Sloan Kettering Cancer Center, where she gained expertise in\u00a0<\/span>cancer genomics<\/strong>, genetic manipulation of transgenic animal models, and pre-clinical treatment studies.<\/span>
Currently, research in her lab aims at systematically integrating genomic and functional analyses to<\/span>\u00a0<\/span>identify oncogenic events<\/strong>\u00a0in cancer and exploit this information for the<\/span>\u00a0<\/span>design of novel therapies<\/strong>.\u00a0<\/span>
Throughout her career, she has identified oncogenes or tumor suppressor genes as new therapeutic targets or as biomarkers to better classify cancer patients. She has integrated linear cancer genomic analyses with tridimensional analyses of the genome to better understand tumor development and evolution.\u00a0<\/span><\/p>\n